What were Rossari Biotech's third-quarter financial results?

Rossari Biotech reported a 3.2% increase in net profit to ₹32.7 crore and a 13.4% rise in revenue to ₹581.6 crore for Q3.

Did Rossari Biotech's profit margins improve in Q3?

No, Rossari Biotech's profit margins contracted to 11.8% in the third quarter, down from 12.6% in the previous year.

How did Rossari Biotech's stock perform recently?

Rossari Biotech's stock ended the previous session down nearly 1%, and has declined 33.6% in the past year.

Home / Business and Economy / Rossari Biotech Q3: Profit Up, Margins Dip

Rossari Biotech Q3: Profit Up, Margins Dip

17 Jan

•

Summary

Net profit increased by 3.2% to ₹32.7 crore.
Revenue saw a 13.4% jump to ₹581.6 crore.
Company margins contracted to 11.8% from 12.6%.

Rossari Biotech Q3: Profit Up, Margins Dip

Mumbai-based specialty chemical firm Rossari Biotech Ltd. announced its financial results for the third quarter on Saturday, January 17, 2026. The company reported an increase in its net profit, revenue, and EBITDA compared to the same period last year. Despite these gains, Rossari Biotech's profit margins experienced a contraction.

The company's net profit saw a 3.2% rise, reaching ₹32.7 crore, up from ₹31.7 crore in the prior year's third quarter. Concurrently, revenue grew by 13.4% to ₹581.6 crore, compared to ₹512.7 crore in the previous fiscal's third quarter. Earnings before interest, tax, depreciation, and amortization (EBITDA) also climbed by 6.3% year-on-year to ₹68.8 crore.

However, a key concern was the contraction in the company's margins, which decreased to 11.8% from 12.6% reported in the corresponding period of the previous year. In related market news, shares of Rossari Biotech closed nearly 1% lower in the previous trading session at ₹534.5 per share, reflecting a 33.6% decline over the past year.